Prices & performance Investment updates Latest insights Invest now
Prices & performance Investment updates Latest insights Invest now

Please note the name of the Antipodes China Fund changed from the Premium China Fund on 22 April 2024.

Antipodes China Fund

The Antipodes China Fund aims to achieve the investment objective by investing in companies across a range of market capitalisations listed in Hong Kong, Mainland China, Macau and Taiwan (Greater China) and companies listed on other exchanges, which have significant assets, investments, production activities, trading or other business interests in the greater China region, or which derive a significant portion or their revenue from the greater China region.

This product is intended for use as a minor or satellite portfolio allocation for a consumer who is seeking capital growth and has a high or very high risk and return profile for that portion of their investment portfolio. It is likely to be consistent with the financial situation and needs of a consumer with a minimum 5-year investment timeframe and who is unlikely to need to withdraw their money on less than one week’s notice.
This product is classified as a Hedge Fund under ASIC Regulatory Guide RG240 and may have complex features. This product is likely to be suitable for investors who have received personal advice.

Key facts

wdt_ID Title Detail
1 Investment manager Antipodes Partners Limited
21 Responsible entity Equity Trustees Limited
22 Strategy China Equity
23 Investment objective The Fund aims to provide long-term capital growth over a three-to-five year horizon.
24 Benchmark
25 Suggested minimum investment period 5 years
26 Risk High
27 Portfolio Allocation1 80-100% Global equities
0-20% Cash
28 Registration Australia
29 Dealing frequency & cut-off Daily / 2pm Sydney
30 Distribution frequency Annually, 30 June
31 Minimum initial investment A$25,000
32 Minimum additional investment A$10,000
33 Strategy inception date Oct-05
34 ISIN
35 APIR MAQ0441AU
36 ARSN 116 380 771
37 Bloomberg code PRCHINA:AU

1The portfolio allocation ranges provided are indicative only. The Fund will be rebalanced within a reasonable period of time should the exposure move outside these ranges.

Net performance

Returns greater than 1 year are annualised. Past performance is no indication of future performance. 1Inception is 28 October 2005. 2Benchmark is MSCI China Index (net div.).

The Fund was previously known as the Premium China Fund. Antipodes Partners Limited became the Investment Manager of the Fund effective 22 April 2024.

Performance chart

Cumulative performance (over selected time horizon)

Returns greater than 1 year are annualised. Past performance is no indication of future performance. Calculations are based on exit price with distributions reinvested.

Unit price history

Distribution history

Portfolio profile as at 31st October 2024

Top 10 equity longs (%)

Sector exposure (%)2

Regional exposure (%)1, 3

1 Where possible, regions, countries and currencies classified on a look through basis. 2 GICS Classification. 3 Antipodes Partners classification.

Monthly updates

For historical reports, please contact the Antipodes team

Quarterly updates

For historical reports, please contact the Antipodes team

mFund

Annual Financial Statement

Other Documents

Invest

If you are applying using paper application forms, the minimum investment in the Antipodes China Fund is $25,000 for new investors and $10,000 for existing investors.

Who may invest in the fund

This fund is open to investors from Australia and New Zealand.

Important information

It is a legal requirement to download and read the Product Disclosure Statement before proceeding and we recommend that you consult a licensed financial advisor before making investment decisions.

Download Product Disclosure Statement (PDS).

Download Product Disclosure Statement (PDS) – NZ.

Download Target Market Determination (TMD).

Apply online

The application below allows you to invest in the Antipodes China Fund.

If you are applying using paper application forms, the minimum investment in the Antipodes China Fund is $25,000 for new investors and $10,000 for existing investors.

Apply online

Apply via a paper form

Purchase, top-up or sell a managed fund investment the familiar way.

  1. Download an application form here
  2. Complete the application form & sign
  3. Provide certified copies of your identity to verify your identity
  4. Email service@pinnacleinvestment.com

Download an application form.

Check out our investing tools

Our latest insights

Invest online now

Ratings

The Antipodes China Fund has been rated “Approved” by Zenith Investment Partners and “Investment Grade” by Lonsec Research.

 

   

Important information

Equity Trustees Limited (“Equity Trustees”) (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Antipodes China Fund (“the Fund”).  Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT).

This webpage has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the investment manager of the Fund to provide you with general information only. In preparing this webpage, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Antipodes, Equity Trustees nor any of its related parties, their employees or directors, provide and warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product.

Antipodes China Fund’s Target Market Determination is available here. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned  Antipodes China Fund – October 2024) referred to on this website is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.

The Lonsec Rating (assigned as follows: Antipodes China Fund – July 2024) presented in this document are published by Lonsec Research presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to “General Advice” (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec’s Ratings methodology, please refer to our website at https://www.lonsec.com.au/.